Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Body Irradiation and Cladribine Before Allogeneic HSCT in AML and MDS
2024-517477-24-00Phase 2Authorised
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: Progression-free survival at 24 months. Planned start Nov 2024; status: authorised.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-517477-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517477-24-00.